Study of Pembrolizumab (MK-3475) in Participants with Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Trial Identifier: 3475-158
Sponsor: MSD
Start Date: December 2015
Primary Completion Date: May 2027
Study Completion Date: May 2027
Condition: Cancer - Other; Gallbladder Cancer; Endometriosis; Lung Cancer; Endometrial Cancer; Mental Health & Behavior - Other; Thyroid Cancer; Colorectal Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary-English

Trial Locations

Country Location
Australia North Ryde, Australia
Brazil Sao Paulo, Brazil
Chile Santiago, Chile
Colombia Bogota, Colombia
Denmark Glostrup, Denmark
France Paris, France
Germany Haar, Germany
Israel Hod Hasharon, Israel
Italy Rome, Italy
Korea, Republic of Seoul, Korea, Republic of, 4130
Mexico Mexico City, Mexico
Netherlands Haarlem, Netherlands
Norway Drammen, Norway
Peru Lima, Peru
Poland Warsaw, Poland
Portugal Paco D'arcos, Portugal
Russian Federation Moscow, Russian Federation
South Africa Midrand, South Africa
Spain Madrid, Spain
United States, NJ New Brunswick, NJ, United States, 08903